Advertisement

Rheumatology International

, Volume 37, Issue 12, pp 1949–1956 | Cite as

Urolithiasis as an extraarticular manifestation of ankylosing spondylitis

  • Cengiz KorkmazEmail author
  • Döndü Üsküdar Cansu
  • John A. Sayer
Review on RMDs

Abstract

Ankylosing spondylitis (AS) affects sacroiliac and axial joints as well as extraarticular organs, such as the eye, lung, bowel, and heart. Although examples of renal involvement in AS, such as IgA nephropathy, amyloidosis, and glomerulonephritis, have been reported, it has not been emphasized that urolithiasis is frequently formed in the clinical course of AS. Growing evidence indicates that urolithiasis may be observed in AS patients and is more frequent than other extraarticular features. In this review, we will discuss frequency and predictors of AS-related urolithiasis and summarize the possible underlying genetic and biochemical mechanisms. We believe an increased awareness of urolithiasis as a complication of AS will encourage future studies that will shed light on disease mechanisms and preventative therapies.

Keywords

Ankylosing spondylitis Urolithiasis Nephrolithiasis Renal stone Bone Intestinal inflammation 

Notes

Funding

This study was not funded by any company or other society.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participant performed by any of the authors.

References

  1. 1.
    Van der Heijde D (2008) Ankylosing spondylitis. In: Klippel JH, Stone JH, Crofford LJ, White PH (eds) Primer on the rheumatic disease, 13th edn. Springer, BerlinGoogle Scholar
  2. 2.
    Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(Suppl 3):8–18CrossRefGoogle Scholar
  3. 3.
    El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560CrossRefPubMedGoogle Scholar
  4. 4.
    Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology 48:1029–1035CrossRefPubMedGoogle Scholar
  5. 5.
    Korkmaz C, Ozcan A, Akçar N (2005) Increased frequency of ultrasonographic findings suggestive of renal stones in patients with ankylosing spondylitis. Clin Exp Rheumatol 23:389–392PubMedGoogle Scholar
  6. 6.
    Jakobsen AK, Jacobsson LT, Patschan O, Askling J, Kristensen LE (2014) Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS ONE 25:9Google Scholar
  7. 7.
    Lui NL, Carty A, Haroon N, Shen H, Cook RJ, Inman RD (2011) Clinical correlates of urolithiasis in ankylosing spondylitis. J Rheumatol 38:1953–1956CrossRefPubMedGoogle Scholar
  8. 8.
    Jakobsen AK, Jacobsson LT, Patschan O, Hopfgarten T, Askling J, Kristensen LE (2015) Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population. Scand J Urol 21:1–6Google Scholar
  9. 9.
    Elian N, Berinde L, Georgescu L, Ocica I, Saba I (1972) Nephro-uropathic manifestations in ankylopoietic spondylitis. Med Interna 24:187–193Google Scholar
  10. 10.
    Mladenovic V (1973) Nephrolithiasis in ankylosing spondylitis. Rheumatizam 20:106–110Google Scholar
  11. 11.
    Jimenez Balderas FJ, Robles EJ, Juan L, Badui E, Arellano H, Espinosa Said L et al (1989) Purine metabolism in ankylosing spondylitis: clinical study. Arch Invest Med 20:163–170Google Scholar
  12. 12.
    Incel NA, Gökoğlu F, Nacir B, İncel N (2006) Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 25:667–670CrossRefPubMedGoogle Scholar
  13. 13.
    Canales BK, Leonard SM, Singh JA, Orzano IM, Zimmermann B, Weiland D et al (2006) Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 20:542–546CrossRefPubMedGoogle Scholar
  14. 14.
    Cansu DU, Calışır C, Savaş Yavaş U, Kaşifoğlu T, Korkmaz C (2011) Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. Clin Rheumatol 30:557–562CrossRefPubMedGoogle Scholar
  15. 15.
    Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoudi M, Paragomi P, Nicknam MH et al (2012) Urolithiasis in ankylosing spondylitis: correlation with BASDAI, BASFI and BASMI. Caspian J Intern Med 3:508–513PubMedPubMedCentralGoogle Scholar
  16. 16.
    Resorlu H, Adam G, Aylanc N, Akbal A, Ozdemir H (2015) Prospective evaluation of the renal morphology and vascular resistance inpatients with ankylosing spondylitis. Med Ultrason 17:180–184CrossRefPubMedGoogle Scholar
  17. 17.
    Moe OW (2006) Kidney Stones: pathophysiology and medical management. Lancet 367(9507):333–344CrossRefPubMedGoogle Scholar
  18. 18.
    Sakhaee K, Maalouf NM, Sinnott B (2012) Kiney Stones 2012:pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97:1847–1860CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gaspar SR, Mendonça T, Oliveira P, Oliveira T, Dias J, Lopes T (2016) Urolithiasis and crohn’s disease. Urol Ann 8:297–304CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMedGoogle Scholar
  21. 21.
    Pang SW, Davis JC (2006) Clinical aspects of ankylosing spondylitis. In: Weisman MH, Reveille JD, Van der Heijde D (eds) Ankylosing spondylitis and spondyloarthropathies, 1st edn. Mosby, Philadelphia, pp 145–153Google Scholar
  22. 22.
    Mielants H, van den Bosch F (2006) Inflammatory bowel disease spondyloarthritis: epidemiology, clinical features, and treatment. In: Weisman MH, Reveille JD, Van der Heijde D (eds) Ankylosing spondylitis and spondyloarthropathies, 1st edn. Mosby, Philadelphia, pp 65–74CrossRefGoogle Scholar
  23. 23.
    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461–1463CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP (2008) Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 58:1020–1025CrossRefPubMedGoogle Scholar
  25. 25.
    van Sommeren S, Janse M, Karjalainen J, Fehrmann R, Franke L, Fu J, Weersma RK (2014) Extraintestinal manifestations and complications in inflammatory bowel disease: from sharedgenetics to shared biological pathways. Inflamm Bowel Dis 20:987–994PubMedGoogle Scholar
  26. 26.
    Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M et al (2014) Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 73:1746–1748CrossRefPubMedGoogle Scholar
  27. 27.
    Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP et al (2012) Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 14(6):R261CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J (2003) Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52:847–853CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA et al (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 128:2020–2028CrossRefPubMedGoogle Scholar
  30. 30.
    Gönüllü E, Bilge NŞ, Cansu DU, Bekmez M, Musmul A, Akçar N et al (2016) Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithiasis. doi: 10.1007/s00240-016-0911-8 PubMedGoogle Scholar
  31. 31.
    Shodjai-Moradi E, Ebringer A, Abuljadayel I (1992) IgA antibody response to Klebsiella in ankylosing spondylitis measured by immunoblotting. Ann Rheum Dis 51:233–237CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Khalafpour S, Ebringer A, Abuljadayel I et al (1988) Antibodies to Klebsiella and Proteus microorganisms in ankylosing spondytitis and rheumatoid arthritis patients measured by ELISA. Br J Rheumatol 27(suppl 2):86–89CrossRefPubMedGoogle Scholar
  33. 33.
    Yuan GH, Shi GY, Ding YZ (1993) Antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Zhonghua Nei Ka Za Zhi 32:467–469 (in Chinese, English abstract) Google Scholar
  34. 34.
    Veys EM, van Laera M (1973) Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis 32:493–496CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ardiçoğlu O, Atay MB, Ataoğlu H et al (1996) IgA antibodies to Klebsiella in ankylosing spondylitis. Clin Rheumatol 15:573–576CrossRefPubMedGoogle Scholar
  36. 36.
    Muñoz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK et al (2014) Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res 29:1770–1776CrossRefPubMedGoogle Scholar
  37. 37.
    Maghraoui AE (2004) Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71:291–295CrossRefPubMedGoogle Scholar
  38. 38.
    Ou SM, Chen YT, Shih CJ, Tarng DC (2015) Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study. Osteoporos Int 26:1261–1269CrossRefPubMedGoogle Scholar
  39. 39.
    Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41:1349–1356CrossRefPubMedGoogle Scholar
  40. 40.
    Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262CrossRefPubMedGoogle Scholar
  41. 41.
    Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, de Oliveira RM, Silva CA, Bonfa E, Pereira RM (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931CrossRefPubMedGoogle Scholar
  43. 43.
    Gratacós J, Collado A, Pons F, Osaba M, Sanmartí R, Roqué M et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324CrossRefPubMedGoogle Scholar
  44. 44.
    Pacifici R (1997) Idiopathic hypercalciuria and osteoporosis—distinct clinical manifestations of increased cytokine induces bone resorption? J Clin Endocrinol Metab 82:29–31PubMedGoogle Scholar
  45. 45.
    Will R, Bhalla AK, Palmer R, Ring R, Calin A (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet II:1483–1485CrossRefGoogle Scholar
  46. 46.
    Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjörnsson G et al (2015) Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 14(6):7975CrossRefGoogle Scholar
  47. 47.
    Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8:1568–1573PubMedGoogle Scholar
  48. 48.
    Stechman MJ, Loh NY, Thakker RV (2007) Genetics of hypercalciuric nephrolithiasis: renal stone disease. Ann N Y Acad Sci 1116:461–484CrossRefPubMedGoogle Scholar
  49. 49.
    Sayer JA (2008) The genetics of nephrolithiasis. Nephron Exp Nephrol 110:e37–e43CrossRefPubMedGoogle Scholar
  50. 50.
    Tsui FW, Tsui HW, Cheng EY, Stone M, Payne U, Reveille JD et al (2003) Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 48:791–797CrossRefPubMedGoogle Scholar
  51. 51.
    Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW (2005) ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 7(3):R513–R525CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Liu Z, Cui Y, Zhou X, Zhang X, Han J (2013) Association of mineralization-related genes TNAP and ANKH polymorphisms with ankylosing spondylitis in the Chinese Han population. Biosci Trends 7:89–92PubMedGoogle Scholar
  53. 53.
    Korkmaz C, Sayer JA (2012) ANKH and renal stone formation in ankylosing spondylitis. J Rheumatol 39:1756CrossRefPubMedGoogle Scholar
  54. 54.
    Ho AM, Johnson MD, Kingsley DM (2000) Role of the Mouse ank gene in control of tissue calcification and arthritis. Science 289:265–270CrossRefPubMedGoogle Scholar
  55. 55.
    Russell RG (1976) Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 19(Suppl 3):465–478CrossRefPubMedGoogle Scholar
  56. 56.
    Moochhala SH, Sayer JA, Carr G, Simmons NL (2008) Renal calcium stones: insights from the control of bone mineralization. Exp Physiol 93:43–49CrossRefPubMedGoogle Scholar
  57. 57.
    Carr G, Sayer JA, Simmons NL (2007) Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem 20:507–516CrossRefPubMedGoogle Scholar
  58. 58.
    Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Vieira de Sousa E, Pinto P et al (2012) ANKH and susceptibility to and severity of ankylosing spondylitis. J Rheumatol 39(1):131–134CrossRefPubMedGoogle Scholar
  59. 59.
    Timms AE, Zhang Y, Bradbury L, Wordsworth BP, Brown MA (2003) Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 48(10):2898–2902CrossRefPubMedGoogle Scholar
  60. 60.
    Hess B (1998) Drug-induced urolithiasis. Curr Opin Urol 8:331–334CrossRefPubMedGoogle Scholar
  61. 61.
    De Koninck AS, Groen LA, Maes H, Verstraete AG, Stove V, Delanghe JR (2016) Unusual type of kidney stone. Clin Lab 62:235–239CrossRefPubMedGoogle Scholar
  62. 62.
    Erturk E, Casemento JB, Guertin KR, Kende AS (1994) Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 151:1605–1606CrossRefPubMedGoogle Scholar
  63. 63.
    Yanagisawa R, Kamijo T, Nagase Y (1999) A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis. Nihon Hinyokika Gakkai Zasshi 90:462–465 (Japanese) PubMedGoogle Scholar
  64. 64.
    Russinko PJ, Agarwal S, Choi MJ, Kelty PJ (2003) Obstructive nephropathy secondary to sulfasalazine calculi. Urology 62(4):748CrossRefPubMedGoogle Scholar
  65. 65.
    Hoffnung JM, Parker MD, Hartz JW (1982) Papillary necrosis mimicking staghorn calculi. Urology 20:325–327CrossRefPubMedGoogle Scholar
  66. 66.
    Boonen A, Everens JL (2002) Ankylosing spondylitis: what is the cost to society and can it be reduced? Best Pract Res Clin Rheumatol 16:691–705CrossRefPubMedGoogle Scholar
  67. 67.
    Ben-Ami H, Ginesin YI, Behar DM, Fischer D, Edoute Y, Lavy A (2002) Diagnosis and treatment of urinary tract complication in Crohn’s disease: an experience over 15 years. Can J Gastroenterol 16:225–229CrossRefPubMedGoogle Scholar
  68. 68.
    Sato S, Sasaki I, Naito H, Funayama Y, Fukushima K, Shibata C et al (1999) Management of urinary complications in Crohn’s disease. Surg Today 29:713–717CrossRefPubMedGoogle Scholar
  69. 69.
    Boussorra H, Sallami S, Said Y, Chebil M, Najjar T (2013) Evaluation of urinary urolithiasis in Crohn’s disease in Tunisian patients. Tunis Med 91:440–443PubMedGoogle Scholar
  70. 70.
    Keddis MT, Rule AD (2013) Nephrolithiasis and loss of kidney function. Curr Opin Nephrol Hypertens 22:390–396CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Vupputuri S, Soucie JM, McClellan W, Sandler DP (2004) History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 14:222–228CrossRefPubMedGoogle Scholar
  72. 72.
    Akman T, Binbay M, Aslan R et al (2012) Long-term outcomes of percutaneous nephrolithotomy in 177 patients with chronic kidney disease: a single center experience. J Urol 187:173–177CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Cengiz Korkmaz
    • 1
    Email author
  • Döndü Üsküdar Cansu
    • 1
  • John A. Sayer
    • 2
  1. 1.Division of Rheumatology, Department of Internal MedicineEskişehir Osmangazi UniversityEskişehirTurkey
  2. 2.Institute of Genetic Medicine, Newcastle UniversityNewcastle upon TyneUK

Personalised recommendations